m-RNA Synthesis Services

Global m-RNA Synthesis Services Market to Reach US$10.0 Billion by 2030

The global market for m-RNA Synthesis Services estimated at US$7.3 Billion in the year 2024, is expected to reach US$10.0 Billion by 2030, growing at a CAGR of 5.3% over the analysis period 2024-2030. Therapeutic Development, one of the segments analyzed in the report, is expected to record a 6.6% CAGR and reach US$4.4 Billion by the end of the analysis period. Growth in the Vaccine Production segment is estimated at 4.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.9 Billion While China is Forecast to Grow at 5.1% CAGR

The m-RNA Synthesis Services market in the U.S. is estimated at US$1.9 Billion in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.6 Billion by the year 2030 trailing a CAGR of 5.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.9% and 4.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.1% CAGR.

Global m-RNA Synthesis Services Market – Key Trends & Drivers Summarized

Why Are m-RNA Synthesis Services Becoming a Cornerstone in Next-Generation Therapeutics and Vaccine Platforms?

Messenger RNA (mRNA) synthesis services are rapidly evolving into a foundational pillar of the biopharmaceutical ecosystem, particularly in the wake of global attention on mRNA-based COVID-19 vaccines. mRNA functions as the transient intermediary between DNA and protein synthesis, making it a versatile vehicle for encoding disease-specific proteins in therapeutic applications. The demand for high-purity, GMP-grade synthetic mRNA is growing across vaccine development, personalized cancer immunotherapy, protein replacement therapies, and rare disease treatments.

Unlike traditional protein or viral vector-based therapeutics, mRNA-based modalities offer rapid, scalable, and cell-free manufacturing advantages. Their ability to elicit targeted immune responses without the risk of genome integration has opened up new possibilities in infectious disease prevention and oncology. Consequently, drug developers—especially biotech startups and academic consortia—are increasingly outsourcing mRNA synthesis to specialized contract development and manufacturing organizations (CDMOs) that provide optimized transcription protocols, capping technologies, and downstream purification expertise.

How Are Technology Platforms and Process Innovations Accelerating the Evolution of m-RNA Synthesis Services?

The technological landscape of mRNA synthesis is advancing rapidly through innovations in in vitro transcription (IVT) chemistry, enzymatic capping, and sequence optimization. Synthetic DNA templates are transcribed using phage RNA polymerases (e.g., T7, SP6), with improvements in template engineering enhancing stability, translational efficiency, and immune evasion. Modified nucleosides like pseudouridine and 5-methylcytidine are being incorporated to reduce innate immune responses and improve mRNA longevity post-administration.

Cap analogs (such as CleanCap and ARCA) and poly(A) tail length optimization are now routinely integrated into synthesis workflows, improving ribosome recruitment and translation fidelity. CDMOs are offering end-to-end services—including plasmid linearization, IVT reaction, DNase treatment, chromatographic purification, and sterile fill-finish—under GMP or research-use conditions. The integration of automation, single-use bioreactors, and AI-based quality analytics is reducing cycle times, increasing batch consistency, and ensuring compliance with regulatory expectations for nucleic acid therapeutics.

Which Therapeutic Areas and Developer Segments Are Driving Demand for m-RNA Synthesis Services Globally?

Infectious diseases remain the most prominent therapeutic application, particularly with the success of mRNA vaccines for COVID-19 by Moderna and Pfizer-BioNTech. However, oncology is fast emerging as the next frontier, with mRNA being used to encode tumor-specific neoantigens for individualized immunotherapy. Research is also expanding into cardiovascular diseases, autoimmune conditions, metabolic disorders, and genetic deficiencies—where mRNA can be programmed to express functional proteins in vivo, offering transient but potent therapeutic effects.

Academic labs, small biotech firms, and mRNA-focused startups are the most active clients of synthesis service providers due to limited in-house GMP capabilities and the high cost of cleanroom biomanufacturing infrastructure. In parallel, large pharmaceutical companies are increasingly partnering with CDMOs to expand their mRNA pipelines, leveraging external expertise in nucleic acid synthesis, scale-up, and formulation. Government agencies and public-private partnerships are also fueling demand through vaccine stockpile development and pandemic preparedness initiatives.

What Is Driving Long-Term Growth and Competitive Differentiation in the m-RNA Synthesis Services Market?

The growth in the mRNA synthesis services market is driven by the expanding application scope of mRNA-based therapeutics, growing VC investment in mRNA startups, and increasing acceptance of nucleic acid-based modalities by regulatory agencies. Global regulatory frameworks are being adapted to fast-track mRNA candidates under breakthrough therapy and accelerated approval pathways, encouraging development and outsourcing activity. The rise of personalized medicine and neoantigen-specific cancer therapies is fostering a surge in demand for small-batch, customized mRNA synthesis services.

To differentiate in a competitive market, service providers are focusing on platform scalability, IP-protected cap analogs, GMP compliance, and integration with lipid nanoparticle (LNP) formulation services. Some are vertically integrating into DNA template manufacturing and RNA stabilization technologies to offer full-cycle RNA drug development support. As mRNA transitions from emergency vaccine use to mainstream therapeutic applications, robust, reliable, and regulatory-compliant synthesis services will be essential to accelerating innovation and ensuring commercial success in this high-growth segment.

SCOPE OF STUDY:

The report analyzes the m-RNA Synthesis Services market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Application (Therapeutic Development, Vaccine Production, Drug Discovery, Other Applications); Scale of Operation (Research, Commercial); End-User (Biopharmaceutical Companies, Contract Research Organizations, Other End-Users)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 44 Featured) -

• AGC Biologics
• Aldevron
• APExBIO
• Aurigene Pharmaceutical Services
• Biomay
• BioNTech SE
• CELLSCRIPT
• Creative Biogene
• CureVac N.V.
• Eurofins Genomics
• GENEWIZ (Azenta Life Sciences)
• GenScript
• Integrated DNA Technologies
• Merck KGaA
• Moderna, Inc.
• New England Biolabs
• Samsung Biologics
• ST Pharm
• Thermo Fisher Scientific
• TriLink BioTechnologies

AI INTEGRATIONS
We`re transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.